Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T14:10:42.391Z.
Calculation as of: 2026-10-06T14:10:42.391Z.
Quote observation: 2026-10-06T14:05:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 473da95602fdb42a5f780e5c02853506da999e38a33e04168dea7648cb5c925f
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Market Cap
$63.95M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$62.78M
Operating Cash Flow Yield
15.01%
TTM Avg
19.10%
3Y Avg
19.10%
5Y Avg
6.56%
Market Cap
$65.81M
Operating Cash Flow Yield
N/A
TTM Avg
2.92%
3Y Avg
2.92%
5Y Avg
2.92%
Market Cap
$68.12M
Operating Cash Flow Yield
N/A
TTM Avg
76.71%
3Y Avg
76.71%
5Y Avg
76.71%
Market Cap
$59.97M
Operating Cash Flow Yield
N/A
TTM Avg
1.11%
3Y Avg
1.11%
5Y Avg
1.11%
Market Cap
$68.27M
Operating Cash Flow Yield
184.46%
TTM Avg
137.45%
3Y Avg
137.45%
5Y Avg
137.45%
Market Cap
$59.51M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alps Group Inc (ALPS) | $64.06M | N/A | N/A | N/A | N/A |
| Kalaris Therapeutics Inc (KLRS)vs › | $63.95M | N/A | N/A | N/A | N/A |
| Cingulate Inc. (CING)vs › | $65.32M | N/A | N/A | N/A | N/A |
| InterCure Ltd. (INCR)vs › | $62.78M | 15.01% | 19.10% | 19.10% | 6.56% |
| Gossamer Bio, Inc. (GOSS)vs › | $65.81M | N/A | 2.92% | 2.92% | 2.92% |
| Heron Therapeutics, Inc. (HRTX)vs › | $68.12M | N/A | 76.71% | 76.71% | 76.71% |
| Adicet Bio, Inc. (ACET)vs › | $59.97M | N/A | 1.11% | 1.11% | 1.11% |
| Fortress Biotech, Inc. (FBIO)vs › | $68.27M | 184.46% | 137.45% | 137.45% | 137.45% |
| MiNK Therapeutics, Inc. (INKT)vs › | $59.51M | N/A | N/A | N/A | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $68.78M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
